Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services' subsidiary, Optival Health Solutions Private Limited, received a two-day suspension order on the drug license of one of its stores located in Mallikarjuna Nagar Kaman, Telangana. The order was issued by the Assistant Director, Drugs Control Administration, Shameerpet, and received by the company on May 14, 2025. The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940, and the related Rules, 1945. The estimated revenue impact from this two-day suspension is approximately Rs. 0.82 lakhs. The company disclosed this update to the exchanges as required under SEBI Regulation 30.
The financial impact is negligible at under Rs. 1 lakh from a single store suspended for two days, and is unlikely to have any material effect on the company's overall operations or stock price.